関連レポート

線維芽細胞増殖因子（FGF）の世界市場：2034年予測

出版元：Transparency Market Research  出版元について

発行年：2024年6月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 141ページになります。

商品コード：TMR293

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

肝細胞増殖因子の世界市場規模は2023年で7030万ドル、2034年に1億4100万ドル、市場の平均年成長率は6.5%になると予測されています。

当レポートでは、肝細胞増殖因子の市場予測-2034年、各種セグメント別市場分析(タイプ別、用途別、国地域別、等)、COVID-19の影響分析、市場シェア分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■肝細胞増殖因子の世界市場予測2020-2034年
・市場規模(US$)

■タイプ別、市場-2034年
フェーズ III (継続中)
フェーズII（承認済み）
フェーズII（継続中）
フェーズⅠ
前臨床試験
※(市場規模US$)

■申請中別、市場-2034年
腫瘍学
心血管
中枢神経系
血液疾患
※(市場規模US$)

■エンドユーザー別、市場-2034年
製薬/バイオテクノロジー企業
CMO（医薬品製造受託機関）/CDMO（医薬品開発製造受託機関）
研究センター/学術機関
※(市場規模US$)

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照


■市場分析
市場ダイナミクス（促進要因、障壁、機会）
パイプライン分析
COVID-19の影響分析
競合状況
市場シェア分析

■肝細胞増殖因子の主要企業プロフィール動向
ViroMed
AnGes, Inc.
M3 Biotechnology, Inc.
AVEO Pharmaceuticals, Inc.
Molecular Partners AG
YooYoung Pharmaceutical Co., Ltd.
F-star Therapeutics Inc.
Galaxy Bio Tech
Kringle Pharma
（全141頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Hepatocyte Growth Factors (HGFs) Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2020-2034
6.3.1. Phase III (Ongoing)
6.3.2. Phase II (Approved)
6.3.3. Phase II (Ongoing)
6.3.4. Phase I
6.3.5. Preclinical
6.4. Market Attractiveness Analysis, by Type

7. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2020-2034
7.3.1. Oncology
7.3.2. Cardiovascular
7.3.3. Central Nervous System
7.3.4. Hematological Disorders
7.4. Market Attractiveness Analysis, by Application

8. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Pharmaceutical and Biotechnology Companies
8.3.2. CMOs and CDMOs
8.3.3. Research Centers & Academic Institutes
8.4. Market Attractiveness Analysis, by End-user

9. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type, 2020-2034
10.3.1. Phase III (Ongoing)
10.3.2. Phase II (Approved)
10.3.3. Phase II (Ongoing)
10.3.4. Phase I
10.3.5. Preclinical
10.4. Market Value Forecast, by Application, 2020-2034
10.4.1. Oncology
10.4.2. Cardiovascular
10.4.3. Central Nervous System
10.4.4. Hematological Disorders
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Pharmaceutical and Biotechnology Companies
10.5.2. CMOs and CDMOs
10.5.3. Research Centers & Academic Institutes
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Type
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country

11. Europe Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type, 2020-2034
11.3.1. Phase III (Ongoing)
11.3.2. Phase II (Approved)
11.3.3. Phase II (Ongoing)
11.3.4. Phase I
11.3.5. Preclinical
11.4. Market Value Forecast, by Application, 2020-2034
11.4.1. Oncology
11.4.2. Cardiovascular
11.4.3. Central Nervous System
11.4.4. Hematological Disorders
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Pharmaceutical and Biotechnology Companies
11.5.2. CMOs and CDMOs
11.5.3. Research Centers & Academic Institutes
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region

12. Asia Pacific Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type, 2020-2034
12.3.1. Phase III (Ongoing)
12.3.2. Phase II (Approved)
12.3.3. Phase II (Ongoing)
12.3.4. Phase I
12.3.5. Preclinical
12.4. Market Value Forecast, by Application, 2020-2034
12.4.1. Oncology
12.4.2. Cardiovascular
12.4.3. Central Nervous System
12.4.4. Hematological Disorders
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Pharmaceutical and Biotechnology Companies
12.5.2. CMOs and CDMOs
12.5.3. Research Centers & Academic Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region

13. Latin America Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type, 2020-2034
13.3.1. Phase III (Ongoing)
13.3.2. Phase II (Approved)
13.3.3. Phase II (Ongoing)
13.3.4. Phase I
13.3.5. Preclinical
13.4. Market Value Forecast, by Application, 2020-2034
13.4.1. Oncology
13.4.2. Cardiovascular
13.4.3. Central Nervous System
13.4.4. Hematological Disorders
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Pharmaceutical and Biotechnology Companies
13.5.2. CMOs and CDMOs
13.5.3. Research Centers & Academic Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region

14. Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Type, 2020-2034
14.3.1. Phase III (Ongoing)
14.3.2. Phase II (Approved)
14.3.3. Phase II (Ongoing)
14.3.4. Phase I
14.3.5. Preclinical
14.4. Market Value Forecast, by Application, 2020-2034
14.4.1. Oncology
14.4.2. Cardiovascular
14.4.3. Central Nervous System
14.4.4. Hematological Disorders
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Pharmaceutical and Biotechnology Companies
14.5.2. CMOs and CDMOs
14.5.3. Research Centers & Academic Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. ViroMed
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. AnGes, Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. M3 Biotechnology, Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. AVEO Pharmaceuticals, Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Molecular Partners AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. YooYoung Pharmaceutical Co., Ltd.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. F-star Therapeutics Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Galaxy Bio Tech
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Kringle Pharma
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview

List of Tables

Table 01: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034

Table 02: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 03: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 04: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Region, 2020-2034

Table 05: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country, 2020-2034

Table 06: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034

Table 07: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 08: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 09: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 10: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034

Table 11: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 12: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 13: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 14: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034

Table 15: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 16: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 17: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 18: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034

Table 19: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 20: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 21: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 22: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034

Table 23: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 24: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

Figure 01: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034

Figure 02: Global Hepatocyte Growth Factors (HGFs) Market Revenue (US$ Mn), by Type, 2023

Figure 03: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by Type, 2023

Figure 04: Global Hepatocyte Growth Factors (HGFs) Market Revenue (US$ Mn), by Application, 2023

Figure 05: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by Application, 2023

Figure 06: Global Hepatocyte Growth Factors (HGFs) Market Revenue (US$ Mn), by End-user, 2023

Figure 07: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by End-user, 2023

Figure 08: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by Region, 2023

Figure 09: Global Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast, 2020-2034

Figure 10: Global Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034

Figure 11: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034

Figure 12: Global Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 13: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 14: Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 15: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034

Figure 16: Global Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Region, 2023 and 2034

Figure 17: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034

Figure 18: North America Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 19: North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country, 2024-2034

Figure 20: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country, 2023 and 2034

Figure 21: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034

Figure 22: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 23: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 24: North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034

Figure 25: North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 26:North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034

Figure 27: Europe Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 28: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 29: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 30: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034

Figure 31: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 32: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 33: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034

Figure 34: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 35: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034

Figure 36: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 37: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 38: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 39: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034

Figure 40: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 41: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 42: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034

Figure 43: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 44: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034

Figure 45: Latin America Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 46: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 47: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 48: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034

Figure 49: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 50: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 51: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034

Figure 52: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 53: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034

Figure 54: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 55: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 56: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 57: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034

Figure 58: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 59: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 60: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034

Figure 61: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 62: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034

△ 一番上に戻る